134 related articles for article (PubMed ID: 37262421)
21. DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma.
Fitzgerald AA; Wang S; Agarwal V; Marcisak EF; Zuo A; Jablonski SA; Loth M; Fertig EJ; MacDougall J; Zhukovsky E; Trivedi S; Bhatia D; O'Neill V; Weiner LM
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34737215
[TBL] [Abstract][Full Text] [Related]
22. Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy.
Mortara L; Balza E; Bruno A; Poggi A; Orecchia P; Carnemolla B
Front Immunol; 2018; 9():2905. PubMed ID: 30619269
[TBL] [Abstract][Full Text] [Related]
23. Targeting Natural Killer Cells for Tumor Immunotherapy.
Zhang C; Hu Y; Shi C
Front Immunol; 2020; 11():60. PubMed ID: 32140153
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic gene modified cell based cancer vaccines.
Kozłowska A; Mackiewicz J; Mackiewicz A
Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846
[TBL] [Abstract][Full Text] [Related]
25. Clinical-scale isolation of interleukin-2-stimulated liver natural killer cells for treatment of liver transplantation with hepatocellular carcinoma.
Ohira M; Nishida S; Tryphonopoulos P; Tekin A; Selvaggi G; Moon J; Levi D; Ricordi C; Ishiyama K; Tanaka Y; Ohdan H; Tzakis AG
Cell Transplant; 2012; 21(7):1397-406. PubMed ID: 22469170
[TBL] [Abstract][Full Text] [Related]
26. NK cell-based tumor immunotherapy.
Zhang H; Yang L; Wang T; Li Z
Bioact Mater; 2024 Jan; 31():63-86. PubMed ID: 37601277
[TBL] [Abstract][Full Text] [Related]
27. Single-Cell RNA Sequencing of Tumor-Infiltrating NK Cells Reveals that Inhibition of Transcription Factor HIF-1α Unleashes NK Cell Activity.
Ni J; Wang X; Stojanovic A; Zhang Q; Wincher M; Bühler L; Arnold A; Correia MP; Winkler M; Koch PS; Sexl V; Höfer T; Cerwenka A
Immunity; 2020 Jun; 52(6):1075-1087.e8. PubMed ID: 32445619
[TBL] [Abstract][Full Text] [Related]
28. Natural killer cell dysfunction in cancer and new strategies to utilize NK cell potential for cancer immunotherapy.
Zhang W; Zhao Z; Li F
Mol Immunol; 2022 Apr; 144():58-70. PubMed ID: 35203022
[TBL] [Abstract][Full Text] [Related]
29. Cytokines Orchestrating the Natural Killer-Myeloid Cell Crosstalk in the Tumor Microenvironment: Implications for Natural Killer Cell-Based Cancer Immunotherapy.
Gaggero S; Witt K; Carlsten M; Mitra S
Front Immunol; 2020; 11():621225. PubMed ID: 33584718
[TBL] [Abstract][Full Text] [Related]
30. Discovery of a novel natural killer cell line with distinct immunostimulatory and proliferative potential as an alternative platform for cancer immunotherapy.
Yang HG; Kang MC; Kim TY; Hwang I; Jin HT; Sung YC; Eom KS; Kim SW
J Immunother Cancer; 2019 May; 7(1):138. PubMed ID: 31126350
[TBL] [Abstract][Full Text] [Related]
31. CD122-targeted interleukin-2 and αPD-L1 treat bladder cancer and melanoma via distinct mechanisms, including CD122-driven natural killer cell maturation.
Reyes RM; Zhang C; Deng Y; Ji N; Mukherjee N; Padron AS; Clark CA; Svatek RS; Curiel TJ
Oncoimmunology; 2021; 10(1):2006529. PubMed ID: 34858732
[TBL] [Abstract][Full Text] [Related]
32. Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment.
Zemek RM; De Jong E; Chin WL; Schuster IS; Fear VS; Casey TH; Forbes C; Dart SJ; Leslie C; Zaitouny A; Small M; Boon L; Forrest ARR; Muiri DO; Degli-Esposti MA; Millward MJ; Nowak AK; Lassmann T; Bosco A; Lake RA; Lesterhuis WJ
Sci Transl Med; 2019 Jul; 11(501):. PubMed ID: 31316010
[TBL] [Abstract][Full Text] [Related]
33. Chemokine networks modulating natural killer cell trafficking to solid tumors.
Yao X; Matosevic S
Cytokine Growth Factor Rev; 2021 Jun; 59():36-45. PubMed ID: 33495094
[TBL] [Abstract][Full Text] [Related]
34. Cationic Nanoparticle-Mediated Activation of Natural Killer Cells for Effective Cancer Immunotherapy.
Kim KS; Han JH; Choi SH; Jung HY; Park JD; An HJ; Kim SE; Kim DH; Doh J; Han DK; Kim IH; Park W; Park KS
ACS Appl Mater Interfaces; 2020 Dec; 12(51):56731-56740. PubMed ID: 33290037
[TBL] [Abstract][Full Text] [Related]
35. Association of Germline Variants in Natural Killer Cells With Tumor Immune Microenvironment Subtypes, Tumor-Infiltrating Lymphocytes, Immunotherapy Response, Clinical Outcomes, and Cancer Risk.
Xu X; Li J; Zou J; Feng X; Zhang C; Zheng R; Duanmu W; Saha-Mandal A; Ming Z; Wang E
JAMA Netw Open; 2019 Sep; 2(9):e199292. PubMed ID: 31483464
[TBL] [Abstract][Full Text] [Related]
36. Natural Killer Anti-Tumor Activity Can Be Achieved by
Esteso G; Aguiló N; Julián E; Ashiru O; Ho MM; Martín C; Valés-Gómez M
Front Immunol; 2021; 12():622995. PubMed ID: 33708215
[TBL] [Abstract][Full Text] [Related]
37. Optimizing NK Cell-Based Immunotherapy in Myeloid Leukemia: Abrogating an Immunosuppressive Microenvironment.
Kaweme NM; Zhou F
Front Immunol; 2021; 12():683381. PubMed ID: 34220833
[TBL] [Abstract][Full Text] [Related]
38. Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10.
Bergamaschi C; Pandit H; Nagy BA; Stellas D; Jensen SM; Bear J; Cam M; Valentin A; Fox BA; Felber BK; Pavlakis GN
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461349
[TBL] [Abstract][Full Text] [Related]
39. Surface specifically modified NK-92 cells with CD56 antibody conjugated superparamagnetic Fe
Zhao S; Duan J; Lou Y; Gao R; Yang S; Wang P; Wang C; Han L; Li M; Ma C; Liang X; Liu H; Sang Y; Gao L
Nanoscale; 2021 Nov; 13(45):19109-19122. PubMed ID: 34766615
[TBL] [Abstract][Full Text] [Related]
40. Stable transduction of the interleukin-2 gene into human natural killer cell lines and their phenotypic and functional characterization in vitro and in vivo.
Nagashima S; Mailliard R; Kashii Y; Reichert TE; Herberman RB; Robbins P; Whiteside TL
Blood; 1998 May; 91(10):3850-61. PubMed ID: 9573023
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
